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Abstract 
 
Background: Eurotransplant „senior“program (ESP) allocates kidneys from elderly donors to 
the patients who are older than 65 years. It is targeted to increase the number of renal 
transplantations. Kidneys are allocated locally without HLA matching to decrease the cold 
ischemia time. Croatia has introduced its own “senior” program based on HLA matching. Our 
results are compared with those from ET.  
Methods: All patients who underwent first renal transplantation at the age of 65 years or older 
were identified and followed-up prospectively. Their HLA matching, cold ischemia time, 
renal function, surgical and medical complications, and duration of hospitalization were 
recorded. 
Results: Until the October 2007, 22 elderly patients received an allograft from donors who 
were older than 65 years. There were 8 female and 14 male patients, with the mean age at 
transplantation of 67.4 years. Mean donor age was 66 years. Number of HLA-MM ranged 
from 1 to 5, and cold-ischaemia time from 7 to 15 hours. One-year patient survival was 95.4 
%, and graft survival was 81.8 %. Delayed graft function, defined as the need for dialysis for 
more than 7 days after transplantation, occurred in 63.6% of patients. Older recipients 
required prolonged hospitalization for transplantation (45, range 16-131). Posttransplant 
complications were frequent and included posttransplant diabetes mellitus in one patient, 
delayed wound healing in 5 patients and lymphocaele in 2 patients. Maligancies occurred in 
three patients (neoplasm of native kidney, posttransplant lymphoproliferative disease and skin 
cancer). One patient experienced acute rejection that was successfully treated with steroids. 
Seventeen patients had 20 viral infections. There was only one serious infection (pulmonary 
tuberculosis). The major problems were cardiovascular complications which occurred in 40.9 
% of patients after transplantation. 
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Conclusion: Renal transplantation in elderly patients is associated with increased incidence of 
posttransplant surgical and medical complications which demand prolonged hospitalization. 
Incidence of acute rejections in elderly patients is significantly decreased with HLA matching, 
without prolongation of the cold ischemia time. Good results justify renal transplantation in 
this group of patients. 
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Introduction 
 
Renal transplantation is method of choice for treatment of patients with end-stage renal disease 
(ESRD) without contraindications for transplantation. It is associated with an improved life 
expectancy and quality of life when compared to dialysis even in elderly patients (1,2). However, 
because of the widening gap between demand and supply of donor organs, transplantation is 
infrequently offered to older persons with ESRD. The Eurotransplant Senior Program (ESP) was 
launched in January 1999 to increase number of transplantations in elderly patients. It allocates 
kidneys from donors who are older than 65 years to recipients of the same age. Only patients with low 
immunological risk (first transplantation and panel reactive antibodies<5%) are considered for 
transplantations. Kidneys are allocated locally to reduce cold ischemia time to recipients with 
compatible ABO-blood group with negative crossmatch. The program does not include HLA matching 
(3). Croatia has introduced “senior” program based on ESP, but with HLA matching. The purpose of 
this study was to evaluate patient and graft survival in elderly patients who received organs from 
elderly donors based on HLA matching and to compare these results with results from ESP. 
 
Patients and methods 
All patients aged 65 years or more at transplantation who received kidney from donor older than 65 
years were included in investigation.  
Pretransplant evaluation 
Patients underwent extensive evaluation before placement on the waiting list for transplantation. Only 
patients without significant comorbidities in good overall clinical status were added to the waitlist. 
Patient’s history was recorded with the special emphasis on cardiovascular status. Coronary heart 
disease, hypertension, stroke, reduced left ventricular function, cardiac arrhythmias, valvular diseases, 
peripheral vascular disease and history of pulmonary embolism were noted. We also recorded 
presence of gastrointestinal problems, different infections and history of malignancies. 
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Baseline characteristics were extracted from the pretransplant evaluation and included duration and 
modality of renal replacement therapy, vascular access for dialysis, body mass index calculated as the 
weight in kilograms divided by square of high in meters. Hepatitis B, hepatitis C, and cytomegalovirus 
(CMV) status before transplantation were noted.  
Donor age, gender, cold ischemia time, and number of HLA mismatches were recorded.  
Posttransplant monitoring 
Patients were followed-up prospectively after transplantation. Surgical complications, delayed graft 
function defined as need for dialysis for longer than 7 days after transplantation, number of dialysis 
sessions after transplantation, length of hospitalization after transplantation, additional hospitalizations 
and acute rejections, with detailed information on immunosuppressive regimen for each patient were 
recorded. Date and reason of death or graft loss were noted.  
Cytomegalovirus infection was defined as positive early antigen in blood culture or positive 
polymerase chain reaction assay. Cytomegalovirus disease was defined as symptomatic CMV 
infection. Treatment of CMV infection consisted of intravenous gancyclovir or oral valgancyclovir 
with concomitant reduction of immunosuppression.  
Posttransplant renal allograft function was determined by measurement of serum creatinine levels and 
calculation of glomerular filtration rate with the Cockroft-Gault formula. 
Data are reported as mean and ranges.  
 
RESULTS 
From January 2004 to October 2007, 286 patients received kidney transplant at our centre. Twenty-
two patients (7.69 %) were older than 65 years at the time of transplantation and received kidney from 
donor older than 65.  
 
Patient’s characteristics at transplantation 
There were 8 female and 14 male patients, with the mean age at transplantation of 67 years. Mean 
donor (45.45 % female) age was 66 years. Number of HLA-MM ranged from 1 to 5, and cold-
ischaemia time from 7 to 15 hours. Detailed patients’ characteristics are presented in Table 1.  
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Table 1. 
 
Immunosuppressive treatment 
Five patients (22.7 %) had more than 3 HLA mismatches and received daclizumab induction. Initial 
immunosuppression in all patients consisted of cyclosporine A (trough levels 150-200 mg/ml), 
mycophenolate mofetil 2x1 g, and steroids. Out of 18 patients with the functioning graft at one year, 3 
patients remained on cyclosporine A and steroids, 2 patients received tacrolimus and steroids, and 3 
patients were switched to sirolimus because of the malignant disease or poor allograft function. All 
other patients continued with the triple immunosuppressive regimen. Dose reduction of 
mycophenolate mofetil was necessary in 55.5 % (10/18), with complete discontinuation in 27.7% 
(5/18) patients (low leukocyte count, gastrointestinal side effects, CMV disease). 
 
Short-term outcome 
Delayed graft function, defined as the need for dialysis for more than 7 days after transplantation, 
occurred in 63.6% of patients. At two weeks posttransplant mean serum creatinine was 245 µmol/l 
(range 145 to 434 µmol/l). One patient died during the initial hospitalization after he suffered from 
stroke and severe bleeding from the gastrointestinal tract. Graftectomy was performed in two patients 
because of the renal vein thrombosis. Short-term posttransplant complications included posttransplant 
diabetes mellitus in one patient, delayed wound healing in 5 patients, and lymphocaele in 2 patients. 
One patient with history of diverticulosis had bowel rupture 20 days after transplantation. Prompt 
surgical intervention saved his life. Graft function remained stable. Complications caused prolonged 
hospitalizations for transplantation (45, range 16-131). Two patients had problems with arm swelling 
due to the subclavian vein stenosis at the side of arteriovenous fistula that, in one of them, required 
surgical intervention during the initial hospitalization. 
 
Long-term outcome 
Graft function 
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One-year patient survival was 95.4 %, and death-censored graft survival was 95 %. Overall one-year 
graft survival was 81.8 %. Besides the patients who lost their grafts during the initial hospitalization, 
one female patient underwent graftectomy 9 months after transplantation because of the bleeding 
during the drainage of the lymphocele. She was subsequently diagnosed with the post transplant 
lymphoproliferative disease (PTLD).  Average creatinine clearance of patients with the functioning 
graft at one year was 55.4 ml/min, with serum creatinine 135.73 µmol/l.  
 
Posttransplant complications 
Short- and long-term posttransplant complications were frequent (Table 2).  
 
Table 2. 
 
Most operative complications were wound-related issues (fluid collections, bleeding, dehiscence 
and/or wound infection).  Posttransplant diabetes mellitus occurred in one patient. Acute rejection 
occurred in only one patient 6 months after transplantation and was successfully treated with steroids. 
He received daclizumab induction. One patient developed serious infection (pulmonary tuberculosis) 
that was successfully treated.  
The major problems were cardiovascular complications which occurred in 40.9 % of patients after 
transplantation. Cardiac arrhythmia, stroke, myocardial infarction and peripheral vascular disease 
complicated the posttransplantation course.  
Dyslipidemia was common to all patients, with increase of total and LDL cholesterol, and decrease of 
HDL cholesterol in 16/18 patients with the functioning graft at three months after transplantation. 
Weight gain was not a problem in elderly renal transplant recipients, with majority of them 
maintaining their weight within the normal limits. Only two patients had body weight index above 30 
mg/m2 one year after transplantation. 
Seventeen patients had 20 viral infections after transplantation (17 cytomegalovirus, 1 Epstein-Barr 
virus-associated posttransplant lymphoproliferative disease, 2 herpes zoster infections). 
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Malignancies developed in 3 patients. One patient was diagnosed with clear cell renal carcinoma of his 
native kidney one month after transplantation. He complained of the pain in lumbal spine. Diagnostic 
evaluation demonstrated that the pain was caused by metastatic renal cancer. Nephroureterectomy was 
performed, followed by local irradiation. Patient refused to cease immunosuppressive therapy. He was 
switched to sirolimus and maintained good graft function. At two years after transplantation he 
remained without signs of maligant disease. Female patient with PTLD in the wall of lymphocele 
underwent graftectomy and returned to dialysis. One patient developed basocellular skin cancer 7 
months after transplantation and was switched to sirolimus.  
 
DISCUSSION 
Much controversy exists regarding the renal transplantation in elderly patients. This group is 
considered to have short life expectancy and higher incidence of different posttransplant complications 
(4-6). Ethical issues surrounding the allocation of scarce organs to patients with short life expectancy 
further increase the dilemma regarding the renal transplantation in elderly. Possible solution is use of 
the so-called marginal organs, which are not suitable for transplantation in younger patients, and 
would otherwise be discharged. ESP was targeted to increase the number of renal transplantations in 
elderly. However, only few data have been published regarding the outcome of patients who were 
transplanted in the ESP (3,7-12). In the present study we evaluated outcome of patients who were 
transplanted in Croatian senior program. This program is modification of ESP, while it includes HLA 
matching as the basis for organ allocation.  
High incidence of delayed graft function in our patients may be attributed to the use of calcineurin 
inhibitors. At the time of introduction of “senior” program in Croatia, financial limits disabled regular 
use of interleukin -2 blockers or thymoglobulin for the induction. Our relatively poor short-term 
results regarding the delayed graft function clearly demonstrate superiority of protocols that include 
induction and delayed use of calcineurin inhibitors (CNIs) (13-16). An intriguing possibility is 
complete avoidance of CNIs in elderly patients what may be achieved in patients with favorable HLA 
matching (15). Elderly are generally considered as “immunologically low risk” patients with reduced 
number of naïve T cells, dysfunctional memory cells, increased sensibility to immunosuppression, 
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reduced T-cell receptors, defective T-cell signaling, increased T-suppressor cells, and altered cytokine 
profiles (4,5,17). However, rejection rate observed in ESP group of patients was 38 %, what was much 
higher than expected while 43 % of patients received mono- or polyclonal induction and 47 % were 
treated with triple immunosuppressive therapy (3). Increased incidence of acute rejections was 
observed also by Fritsche et al. (9) who recorded acute rejections in 43.2 % of ESP patients. Acute 
rejections demand the use of intensive immunosuppression. The price is high incidence and mortality 
from severe infections (18). High incidence of infectious complications and deaths argues against 
aggressive immunosuppression in elderly recipients (19-21). One year survival rate of 73 patients 
transplanted in the ESP was 94 % with graft survival of 87 % (22). Other studies obtained lower one-
year patient and graft survival rates (86 % and 79 %, respectively) (3), (85 % and 84 %, respectively) 
(9). Patients transplanted in our centre in the “senior” program had comparable one-year patient (95.4 
% vs. 96.3 %), but lower graft survival (81.8 % vs. 93.6 %) than younger patients transplanted 
according to the national allocation system. 
It was previously believed that short cold ischemia time may balance the detrimental effect of 
immunological risk associated with HLA mismatching (23-25). However, high incidence of acute 
rejections in ESP demonstrated that it would be wise to include HLA matching in the protocol while 
this does not prolong the cold ischemia time significantly if kidneys are allocated locally (26). From 
August 15th 2007, Croatia has joined Eurotransplant and adopted ESP, as well as other programs that 
exist in Eurotransplant. However, we continued with our policy of organ allogation in “senior” 
program based on HLA matching. Frei et al. have recently published 5-year experience with the ESP. 
They conclude that shorter cold ischemia time does not fully mitigate the effect of HLA mismatching 
in the ESP (18). Eurotransplant currently considers introducing the Eurotransplant Senior DR-
compatible Program (ESDP) (18). 
In our experience, initial length of hospital stay was prolonged in elderly recipients. Besides the 
medical reasons, there are often logistic reasons for several additional days of hospitalization. There is 
no designated out-patient-stay facility in our region, and our catchment area includes whole Croatia. 
For this reason many patients who should otherwise be discharged, are kept in hospital because of the 
lack of proper surgical or medical care in their area.  
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The main disadvantage of our study is small sample size and single-centre experience. However, this 
is also an advantage, while all the patients were followed-up prospectively, and all of them underwent 
the same pretransplant and posttransplant evaluation. However, longer follow-up is needed to further 
clarify the role of HLA matching in elderly recipients and to demonstrate that elderly patients are not 
“immunologically inert” (23-25). It may be possible to avoid high mortality rates attributed to septic 
complications in the ESP with implementation of HLA matching, thus avoiding over-
immunosuppression. 
In conclusion, elderly patients should not be excluded from renal transplantation. Thorough 
pretransplant evaluation is mandatory as well as the close posttransplant follow-up. Use of organs 
from elderly donors solves the ethic dilemma surrounding the renal transplantation in elderly 
recipients. Our results demonstrate that HLA matching decrease the incidence of acute rejections in 
“senior” program and may improve outcome after renal transplantation.  
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Table 1. Patients’ characteristics at transplantation. 
 
Characteristic Mean (range) 
Age (years) 
Gender (% female) 
Diabetes mellitus (%) 
Duration of dialysis (months) 
Dialysis modality (%) 
- hemodialysis 
- peritoneal dialysis 
Cardiovascular disease 
History of malignancy 
Number of HLA mismatches 
Cold-ischemia time (hours) 
Body-mass index (kg/m2) 
Hepatitis B (% negative) 
Hepatitis C (% negative) 
CMV status (% IgG negative) 
67.4 (65-68) 
36.7 
18.18 
71 (8-152) 
 
86.4 
13.6 
27.27% 
0% 
2.8 (1-5) 
10.4 (7-15) 
26.9 (22.53-30.99) 
100 
100 
4.5 
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Table 2. Results at one year of follow-up. 
 
Variable  
Patient survival  
Graft survival  
Serum creatinine (µmol/l) 
Creatinine clearance (ml/min) 
BMI (kg/m2) 
Acute rejection (%) 
Readmissions (n) 
     -days of hospitalization 
Malignancy (%) 
PTDM (%) 
CMV infection (%) 
Major infections (%) 
Cardiovascular complications 
     - myocardial infarction 
     - stroke 
     - peripheral vascular disease 
     - pulmonary embolia 
     - cardiac arrhytmia 
95.4 % 
81.8 % 
135.73 (80-227) 
55.4 (30-93) 
26.63 (23.85-30.55) 
1 (4.54%) 
11 
132 
3 (13.63 %) 
1 (4.54 %) 
17 (77.27 %) 
1 (4.54 %) 
9 (40.9 %) 
1 (4.54 %) 
1 (4.54 %) 
2 (9.09 %) 
2 (9.09 %) 
3 (13.63 %) 
 
 
 
 
